

Web-Only References (posted as supplied by the authors)

W1. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. *Circulation* 2005;112:759-70.

W2. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. *J Pharmacol Exp Ther* 1999;289:735-41.

W3. Fitzgerald GA. Coxibs and cardiovascular disease. *N Engl J Med* 2004;351:1709-11.

W4. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclo-oxygenase products and atherothrombosis. *Ann Med* 2000;32 Suppl 1:21-6.

W5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med* 2001;345:433-42.

W6. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and iso-eicosanoid production in inflammation. *J Clin Invest* 2000;105:1473-82.

W7. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. *Blood* 2000;96:3823-6.

W8. DeMets DL, Friedman LM, Furberg CD, editors. *Data monitoring in clinical trials: a case-studies approach*. New York, NY: Springer Publishing Co., 2005.

W9. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. *N Engl J Med* 2006;354:1193.

W10. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," *N Engl J Med* 2000;343:1520-8. *N Engl J Med* 2005;353:2813-4.

- W11. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000;343:1520-8, 2 p following 1528.
- W12. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA* 2001;286:954-9.
- W13. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092-102.
- W14. Correction. *N Engl J Med* 2006;355:221.
- W15. Lagakos SW. Time-to-event analyses for long-term treatments--the APPROVe trial. *N Engl J Med* 2006;355:113-7.
- W16. Furberg CD. Adverse cardiovascular effects of rofecoxib. *N Engl J Med* 2006;355:204; author reply 204-5.
- W17. Nissen SE. Adverse cardiovascular effects of rofecoxib. *N Engl J Med* 2006;355:203-4; author reply 203-5.
- W18. Oberholzer-Gee F, Inamdar SN. Merck's recall of rofecoxib--a strategic perspective. *N Engl J Med* 2004;351:2147-9.
- W19. Eisenberg RS. Learning the value of drugs--is rofecoxib a regulatory success story? *N Engl J Med* 2005;352:1285-7.
- W20. Okie S. Raising the safety bar--the FDA's coxib meeting. *N Engl J Med* 2005;352:1283-5.
- W21. Okie S. What ails the FDA? *N Engl J Med* 2005;352:1063-6.
- W22. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. *N Engl J Med* 2004;351:1707-9.
- W23. Drazen JM. COX-2 inhibitors--a lesson in unexpected problems. *N Engl J Med* 2005;352:1131-2.

- W24. Psaty BM, Furberg CD. COX-2 inhibitors--lessons in drug safety. *N Engl J Med* 2005;352:1133-5.
- W25. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. *Circulation* 2001;104:2280-8.
- W26. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. *Ann Intern Med* 2003;139:539-46.
- W27. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. *JAMA* 1998;280:222-4.
- W28. Rennie D, Flanagin A. Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin. *JAMA* 1994;271:469-71.
- W29. Laine C, Mulrow CD. Exorcising ghosts and unwelcome guests. *Ann Intern Med* 2005;143:611-2.
- W30. Egilman DS, Presler AH. Report of specific cardiovascular outcomes of the ADVANTAGE trial. *Ann Intern Med* 2006;144(10):781.
- W31. Braunstein N, Polis A. Report of specific cardiovascular outcomes of the ADVANTAGE trial. *Ann Intern Med* 2005;143:158-9.
- W32. Hochberg MC. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. *Am J Manag Care* 2002;8(17 Suppl):S502-17.
- W33. Garnett WR. Clinical implications of drug interactions with coxibs. *Pharmacotherapy* 2001;21:1223-32.
- W34. Gloth FM, 3rd. Pain management in older adults: prevention and treatment. *J Am Geriatr Soc* 2001;49:188-99.

W35. Schnitzer TJ. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors. *Clin Ther* 2001;23:313-326; discussion 311-2.

W36. Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. *Clin Ther* 2001;23:1323-38.

W37. Hawthorne F. *The Merck druggernaut: the inside story of a pharmaceutical giant*. New York, NY: John Wiley & Sons, 2003.